The inhibitors pemigatinib, futibatinib, and RLY-4008 showed activity in multiple disease types and FGFR alterations (with RLY-4008 being FGFR2-specific), though additional follow-up is needed to determine the utility of targeting FGFR pan-cancer. The gene discussed is FGFR2; the disease is cancer.